Media room

This section features official updates, announcements, press releases, and key highlights from our brand. Stay informed about company milestones, partnerships, and important media coverage.

text

Lundbeck VYEPTI Study Shows Cognitive Symptom Improvements

Lundbeck has unveiled compelling new data from its INFUSE study demonstrating meaningful improvements in migraine-related cognitive symptoms among patients who switched to VYEPTI after experiencing failures with other anti-CGRP treatments. The one-year real-world evidence study, presented at the American Academy of Neurology conference, tracks patient-reported outcomes over six months in this historically challenging patient population.

Lundbeck VYEPTI Study Shows Cognitive Symptom Improvements Read More »